O	0	1	[
O	1	11	Preventive
O	12	18	effect
O	19	21	of
B-intervention	22	25	low
I-intervention	25	26	-
I-intervention	26	30	dose
I-intervention	31	41	carvedilol
I-intervention	42	50	combined
I-intervention	51	55	with
I-intervention	56	67	candesartan
O	68	70	on
O	71	74	the
B-condition	75	89	cardiotoxicity
O	90	92	of
O	93	106	anthracycline
O	107	112	drugs
O	113	115	in
O	116	119	the
O	120	128	adjuvant
O	129	141	chemotherapy
O	142	144	of
O	145	151	breast
O	152	158	cancer
O	158	159	]
O	159	160	.

O	161	163	To
O	164	175	investigate
O	176	179	the
O	180	186	effect
O	187	189	of
O	190	193	low
O	193	194	-
O	194	198	dose
O	199	209	carvedilol
O	210	218	combined
O	219	223	with
O	224	235	candesartan
O	236	238	in
O	239	242	the
O	243	253	prevention
O	254	256	of
O	257	262	acute
O	263	266	and
O	267	274	chronic
O	275	289	cardiotoxicity
O	290	292	of
O	293	306	anthracycline
O	307	312	drugs
O	313	315	in
O	316	324	adjuvant
O	325	337	chemotherapy
O	338	340	of
O	341	347	breast
O	348	354	cancer
O	354	355	.

B-total-participants	356	361	Forty
O	362	370	patients
O	371	375	were
O	376	384	randomly
O	385	392	divided
O	393	397	into
O	398	401	two
O	402	408	groups
O	408	409	:
O	410	413	the
O	414	426	experimental
O	427	432	group
O	433	437	with
O	438	450	chemotherapy
O	451	455	plus
O	456	459	low
O	459	460	-
O	460	464	dose
O	465	475	carvedilol
O	476	484	combined
O	485	489	with
O	490	501	candesartan
O	502	503	(
B-intervention-participants	503	505	20
O	506	511	cases
O	511	512	)
O	513	516	and
B-control	517	524	control
I-control	525	530	group
O	531	535	with
O	536	548	chemotherapy
O	549	554	alone
O	555	556	(
B-control-participants	556	558	20
O	559	564	cases
O	564	565	)
O	565	566	.

O	567	570	The
O	571	575	same
O	576	588	chemotherapy
O	589	592	was
O	593	598	given
O	599	601	to
O	602	605	the
O	606	609	two
O	610	616	groups
O	616	617	.

O	618	621	All
O	622	625	the
O	626	628	40
O	629	637	patients
O	638	641	had
O	642	644	no
O	645	661	contraindication
O	662	665	for
O	666	676	carvedilol
O	677	680	and
O	681	692	candesartan
O	692	693	.

O	694	702	Patients
O	703	705	of
O	706	709	the
O	710	722	experimental
O	723	728	group
O	729	737	received
O	738	741	low
O	741	742	-
O	742	746	dose
O	747	757	carvedilol
O	758	762	from
O	763	764	2
O	764	765	.
O	765	766	5
O	767	769	mg
O	770	776	orally
O	777	782	twice
O	783	784	a
O	785	788	day
O	789	791	at
O	792	797	first
O	798	803	cycle
O	804	806	to
O	807	808	5
O	809	811	mg
O	812	817	twice
O	818	819	a
O	820	823	day
O	824	833	gradually
O	834	836	if
O	837	839	no
O	840	844	side
O	845	854	reactions
O	854	855	,
O	856	859	and
O	860	871	candesartan
O	872	873	2
O	873	874	.
O	874	875	5
O	876	878	mg
O	879	885	orally
O	886	890	once
O	891	892	a
O	893	896	day
O	896	897	.

O	898	915	Electrocardiogram
O	915	916	,
O	917	927	ultrasonic
O	928	938	cardiogram
O	938	939	,
O	940	950	arrhythmia
O	950	951	,
O	952	960	troponin
O	961	964	and
O	965	968	non
O	968	969	-
O	969	980	hematologic
O	981	989	toxicity
O	990	994	were
O	995	1003	recorded
O	1004	1007	and
O	1008	1016	compared
O	1017	1022	after
O	1023	1026	the
O	1027	1033	second
O	1033	1034	,
O	1035	1040	forth
O	1041	1044	and
O	1045	1050	sixth
O	1051	1056	cycle
O	1057	1059	of
O	1060	1072	chemotherapy
O	1072	1073	.

O	1074	1078	Each
O	1079	1084	cycle
O	1085	1093	included
O	1094	1096	21
O	1097	1101	days
O	1101	1102	.

B-outcome	1103	1107	LVEF
O	1108	1111	was
O	1112	1121	decreased
O	1122	1127	along
O	1128	1132	with
O	1133	1136	the
O	1137	1149	prolongation
O	1150	1152	of
O	1153	1165	chemotherapy
O	1166	1168	in
O	1169	1172	the
O	1173	1185	experimental
O	1186	1191	group
O	1192	1195	and
O	1196	1203	control
O	1204	1209	group
O	1209	1210	.

B-outcome	1211	1216	LVEDD
I-outcome	1217	1220	and
I-outcome	1221	1226	LVESD
O	1227	1233	showed
O	1234	1236	no
O	1237	1248	significant
O	1249	1256	changes
O	1257	1259	in
O	1260	1263	the
O	1264	1276	experimental
O	1277	1282	group
O	1282	1283	,
O	1284	1287	but
O	1288	1297	gradually
O	1298	1307	increased
O	1308	1310	in
O	1311	1314	the
O	1315	1322	control
O	1323	1328	group
O	1328	1329	.

B-outcome	1330	1335	After
I-outcome	1336	1340	four
I-outcome	1341	1344	and
I-outcome	1345	1348	six
I-outcome	1349	1355	cycles
I-outcome	1356	1358	of
I-outcome	1359	1371	chemotherapy
O	1371	1372	,
B-outcome	1373	1377	LVEF
O	1378	1382	were
O	1383	1384	(
B-cv-cont-mean	1384	1386	57
I-cv-cont-mean	1386	1387	.
I-cv-cont-mean	1387	1389	00
O	1390	1391	±
B-cv-cont-sd	1392	1393	5
I-cv-cont-sd	1393	1394	.
I-cv-cont-sd	1394	1396	13
O	1396	1397	)
O	1397	1398	%
O	1399	1402	and
O	1403	1404	(
B-cv-cont-mean	1404	1406	45
I-cv-cont-mean	1406	1407	.
I-cv-cont-mean	1407	1409	95
O	1410	1411	±
B-cv-cont-sd	1412	1413	3
I-cv-cont-sd	1413	1414	.
I-cv-cont-sd	1414	1416	68
O	1416	1417	)
O	1417	1418	%
O	1418	1419	,
O	1420	1432	respectively
O	1432	1433	,
O	1434	1436	in
O	1437	1440	the
O	1441	1448	control
O	1449	1454	group
O	1454	1455	,
O	1456	1469	significantly
O	1470	1475	lower
O	1476	1480	than
O	1481	1485	that
O	1486	1488	of
O	1489	1490	(
B-iv-cont-mean	1490	1492	67
I-iv-cont-mean	1492	1493	.
I-iv-cont-mean	1493	1495	00
O	1496	1497	±
B-iv-cont-sd	1498	1499	5
I-iv-cont-sd	1499	1500	.
I-iv-cont-sd	1500	1502	13
O	1502	1503	)
O	1503	1504	%
O	1505	1508	and
O	1509	1510	(
B-iv-cont-mean	1510	1512	57
I-iv-cont-mean	1512	1513	.
I-iv-cont-mean	1513	1515	50
O	1516	1517	±
B-iv-cont-sd	1518	1519	2
I-iv-cont-sd	1519	1520	.
I-iv-cont-sd	1520	1522	57
O	1522	1523	)
O	1523	1524	%
O	1524	1525	,
O	1526	1538	respectively
O	1538	1539	,
O	1540	1542	in
O	1543	1546	the
O	1547	1559	experimental
O	1560	1565	group
O	1566	1567	(
O	1567	1568	P
O	1569	1570	<
O	1571	1572	0
O	1572	1573	.
O	1573	1575	05
O	1575	1576	)
O	1576	1577	.

B-outcome	1578	1583	After
I-outcome	1584	1587	six
I-outcome	1588	1594	cycles
I-outcome	1595	1597	of
I-outcome	1598	1610	chemotherapy
O	1610	1611	,
B-outcome	1612	1617	LVEDD
O	1618	1621	and
B-outcome	1622	1627	LVESD
O	1628	1632	were
O	1633	1634	(
B-cv-cont-mean	1634	1636	50
I-cv-cont-mean	1636	1637	.
I-cv-cont-mean	1637	1639	00
O	1640	1641	±
B-cv-cont-sd	1642	1644	10
I-cv-cont-sd	1644	1645	.
I-cv-cont-sd	1645	1647	48
O	1647	1648	)
O	1649	1651	mm
O	1652	1655	and
O	1656	1657	(
B-cv-cont-mean	1657	1659	35
I-cv-cont-mean	1659	1660	.
I-cv-cont-mean	1660	1662	01
O	1663	1664	±
B-cv-cont-sd	1665	1666	2
I-cv-cont-sd	1666	1667	.
I-cv-cont-sd	1667	1669	99
O	1669	1670	)
O	1671	1673	mm
O	1673	1674	,
O	1675	1687	respectively
O	1687	1688	,
O	1689	1691	in
O	1692	1695	the
O	1696	1703	control
O	1704	1709	group
O	1709	1710	,
O	1711	1724	significantly
O	1725	1731	higher
O	1732	1736	than
O	1737	1742	those
O	1743	1749	before
O	1750	1762	chemotherapy
O	1763	1764	(
O	1764	1765	P
O	1766	1767	<
O	1768	1769	0
O	1769	1770	.
O	1770	1772	05
O	1772	1773	)
O	1774	1777	and
O	1778	1790	experimental
O	1791	1796	group
O	1797	1798	(
O	1798	1799	P
O	1800	1801	<
O	1802	1803	0
O	1803	1804	.
O	1804	1807	001
O	1807	1808	)
O	1808	1809	.

O	1810	1813	The
B-outcome	1814	1818	rate
I-outcome	1819	1821	of
I-outcome	1822	1824	ST
I-outcome	1825	1832	segment
I-outcome	1833	1836	and
I-outcome	1837	1838	T
I-outcome	1839	1843	wave
I-outcome	1844	1857	abnormalities
O	1858	1861	was
B-cv-bin-percent	1862	1864	80
I-cv-bin-percent	1864	1865	.
I-cv-bin-percent	1865	1866	0
I-cv-bin-percent	1866	1867	%
O	1868	1870	in
O	1871	1874	the
O	1875	1882	control
O	1883	1888	group
B-outcome	1889	1894	after
I-outcome	1895	1898	six
I-outcome	1899	1905	cycles
I-outcome	1906	1908	of
I-outcome	1909	1921	chemotherapy
O	1921	1922	,
O	1923	1936	significantly
O	1937	1943	higher
O	1944	1948	than
O	1949	1953	that
O	1954	1956	of
B-cv-bin-percent	1957	1959	25
I-cv-bin-percent	1959	1960	.
I-cv-bin-percent	1960	1961	0
I-cv-bin-percent	1961	1962	%
B-outcome	1963	1968	after
I-outcome	1969	1973	four
I-outcome	1974	1980	cycles
I-outcome	1981	1983	of
I-outcome	1984	1996	chemotherapy
O	1997	1998	(
O	1998	1999	P
O	2000	2001	=
O	2002	2003	0
O	2003	2004	.
O	2004	2007	001
O	2007	2008	)
O	2009	2012	and
B-cv-bin-percent	2013	2015	10
I-cv-bin-percent	2015	2016	.
I-cv-bin-percent	2016	2017	0
I-cv-bin-percent	2017	2018	%
B-outcome	2019	2024	after
I-outcome	2025	2028	two
I-outcome	2029	2035	cycles
I-outcome	2036	2038	of
I-outcome	2039	2051	chemotherapy
O	2052	2053	(
O	2053	2054	P
O	2055	2056	<
O	2057	2058	0
O	2058	2059	.
O	2059	2062	001
O	2062	2063	)
O	2063	2064	.

O	2065	2068	The
O	2069	2078	reduction
O	2079	2081	of
B-outcome	2082	2085	QRS
I-outcome	2086	2093	voltage
O	2093	2094	,
B-outcome	2095	2105	arrhythmia
O	2106	2109	and
B-outcome	2110	2118	abnormal
I-outcome	2119	2127	troponin
O	2128	2132	were
B-cv-bin-percent	2133	2135	55
I-cv-bin-percent	2135	2136	.
I-cv-bin-percent	2136	2137	0
I-cv-bin-percent	2137	2138	%
O	2138	2139	,
B-cv-bin-percent	2140	2142	45
I-cv-bin-percent	2142	2143	.
I-cv-bin-percent	2143	2144	0
I-cv-bin-percent	2144	2145	%
O	2146	2149	and
B-cv-bin-percent	2150	2152	45
I-cv-bin-percent	2152	2153	.
I-cv-bin-percent	2153	2154	0
I-cv-bin-percent	2154	2155	%
I-cv-bin-percent	2155	2156	,
O	2157	2169	respectively
O	2169	2170	,
O	2171	2173	in
O	2174	2177	the
O	2178	2185	control
O	2186	2191	group
O	2191	2192	,
O	2193	2206	significantly
O	2207	2213	higher
O	2214	2218	than
O	2219	2224	those
O	2225	2227	in
O	2228	2231	the
O	2232	2244	experimental
O	2245	2250	group
O	2251	2252	(
B-iv-bin-percent	2252	2254	20
I-iv-bin-percent	2254	2255	.
I-iv-bin-percent	2255	2256	0
I-iv-bin-percent	2256	2257	%
O	2257	2258	,
O	2259	2260	P
O	2261	2262	<
O	2263	2264	0
O	2264	2265	.
O	2265	2267	05
O	2267	2268	)
O	2268	2269	,
O	2270	2271	(
B-iv-bin-percent	2271	2273	10
I-iv-bin-percent	2273	2274	.
I-iv-bin-percent	2274	2275	0
I-iv-bin-percent	2275	2276	%
O	2276	2277	,
O	2278	2279	P
O	2280	2281	=
O	2282	2283	0
O	2283	2284	.
O	2284	2287	010
O	2287	2288	)
O	2289	2292	and
O	2293	2294	(
B-iv-bin-percent	2294	2296	10
I-iv-bin-percent	2296	2297	.
I-iv-bin-percent	2297	2298	0
I-iv-bin-percent	2298	2299	%
O	2299	2300	,
O	2301	2302	P
O	2303	2304	<
O	2305	2306	0
O	2306	2307	.
O	2307	2309	05
O	2309	2310	)
O	2310	2311	,
O	2312	2324	respectively
O	2324	2325	.

O	2326	2329	The
B-outcome	2330	2334	rate
I-outcome	2335	2337	of
I-outcome	2338	2346	abnormal
I-outcome	2347	2357	expression
I-outcome	2358	2360	of
I-outcome	2361	2369	troponin
O	2370	2373	was
B-cv-bin-percent	2374	2376	45
I-cv-bin-percent	2376	2377	.
I-cv-bin-percent	2377	2378	0
I-cv-bin-percent	2378	2379	%
O	2380	2382	in
O	2383	2386	the
O	2387	2394	control
O	2395	2400	group
O	2400	2401	,
O	2402	2415	significantly
O	2416	2422	higher
O	2423	2427	than
O	2428	2431	the
B-iv-bin-percent	2432	2434	10
I-iv-bin-percent	2434	2435	.
I-iv-bin-percent	2435	2436	0
I-iv-bin-percent	2436	2437	%
O	2438	2440	in
O	2441	2444	the
O	2445	2457	experimental
O	2458	2463	group
O	2464	2465	(
O	2465	2466	P
O	2467	2468	<
O	2469	2470	0
O	2470	2471	.
O	2471	2473	05
O	2473	2474	)
O	2474	2475	.

O	2476	2479	The
O	2480	2483	use
O	2484	2486	of
O	2487	2490	low
O	2490	2491	-
O	2491	2495	dose
O	2496	2506	carvedilol
O	2507	2515	combined
O	2516	2520	with
O	2521	2532	candesartan
O	2533	2536	can
O	2537	2543	reduce
O	2544	2547	the
O	2548	2553	acute
O	2554	2557	and
O	2558	2565	chronic
O	2566	2580	cardiotoxicity
O	2581	2583	of
O	2584	2597	anthracycline
O	2598	2603	drugs
O	2603	2604	,
O	2605	2608	and
O	2609	2613	with
O	2614	2623	tolerable
O	2624	2634	toxicities
O	2634	2635	.

O	2636	2640	This
O	2641	2644	may
O	2645	2652	provide
O	2653	2654	a
O	2655	2658	new
O	2659	2667	approach
O	2668	2670	to
O	2671	2678	prevent
O	2679	2693	cardiotoxicity
O	2694	2696	of
O	2697	2710	anthracycline
O	2711	2716	drugs
O	2717	2719	in
O	2720	2728	adjuvant
O	2729	2741	chemotherapy
O	2742	2744	of
O	2745	2751	breast
O	2752	2758	cancer
O	2758	2759	.
